Log In
person
Mitsubishi Tanabe Pharma Corp
MTZPY
summarize
5 total product lines
calendar_month
Revenue as of 03/31/2019
| Reporting Segmentarrow_drop_up | Product Line | Amount (JPY) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (JPY) | Percentage |
| Domestic Ethical Drugs |
Generic Pharmaceuticals
These companies manufacture generic drugs.
|
298B | 70.32% |
| OTC products |
Over-the-Counter Pharmaceuticals
These companies research, develop, and manufacture over-the-counter (OTC) drugs, or those that do not require a doctor's prescription.
|
3.7B | 0.87% |
| Other |
Generic Pharmaceuticals
These companies manufacture generic drugs.
|
3.9B | 0.92% |
| Overseas Ethical Drugs |
Generic Pharmaceuticals
These companies manufacture generic drugs.
|
55.1B | 13.00% |
| Royalty Revenue, etc. |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
63.1B | 14.89% |
| keyboard_arrow_down |
Domestic Ethical Drugs
Generic Pharmaceuticals
|
298B | 70.32% |
| keyboard_arrow_right |
These companies manufacture generic drugs.
|
||
| keyboard_arrow_down |
OTC products
Over-the-Counter Pharmaceuticals
|
3.7B | 0.87% |
| keyboard_arrow_right |
These companies research, develop, and manufacture over-the-counter (OTC) drugs, or those that do not require a doctor's prescription.
|
||
| keyboard_arrow_down |
Other
Generic Pharmaceuticals
|
3.9B | 0.92% |
| keyboard_arrow_right |
These companies manufacture generic drugs.
|
||
| keyboard_arrow_down |
Overseas Ethical Drugs
Generic Pharmaceuticals
|
55.1B | 13.00% |
| keyboard_arrow_right |
These companies manufacture generic drugs.
|
||
| keyboard_arrow_down |
Royalty Revenue, etc.
Pharmaceutical Patent Licensing
|
63.1B | 14.89% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||